Please assess the completion status of the following clinical trial:

Trial Title: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Diagnosis of multiple myeloma (MM) requiring systemic therapy~* Age greater than or equal to (\>=) 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Life expectancy greater than (\>) 3 months~* Relapsed from or refractory to two or more different prior therapies~* Signed Informed consent~Exclusion criteria~* Plasma cell leukemia defined as a plasma cell count \> 2000/millimeter\^3 (mm\^3)~* Known amyloidosis~* Participants who previously have received an allogeneic stem cell transplant~* Sensory or motor neuropathy of \>= grade 3~* Past or current malignancy~* Chronic or ongoing active infectious disease~* Clinically significant cardiac disease~* Significant concurrent, uncontrolled medical condition including, but not limited to, renal (except related to MM), hepatic, hematological except MM, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease~* A baseline QT interval as corrected by Fridericia's formula \> 470 millisecond (msec) for female participants or \> 450 msec for male participants or a complete left bundle branch block (defined as a QRS interval \>= 120 msec in left bundle branch block form)~* Hypokalemia~* Clinical signs of meningeal involvement of MM~* Known severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume in 1 second (FEV1) less than (\<) 60 percentage (%) of expected~* History of significant cerebrovascular disease~* Known Human Immunodeficiency Virus seropositivity~* Positive serology for hepatitis B~* Screening laboratory values~* Concomitant corticosteroid~* Other chemotherapy that is or may be active against myeloma within 3 weeks prior to Visit 2 (Part 1) or the first dose of daratumumab (Part 2). However, corticosteroid for myeloma (less than a 4-day course) could be administered within 1 week before Visit 2 (Part 1) or the first dose of daratumumab (Part 2)~* Known hypersensitivity to components of the investigational product or severe allergic or anaphylactic reactions to humanized products~* Participants who have received treatment with any nonmarket drug substance within 4 weeks before the first dose of daratumumab~* Current participation in any other interventional clinical trial~* Participants known or suspected of not being able to comply with a trial protocol (example, due to alcoholism, drug dependency, or psychological disorder)~* Breastfeeding women or women with a positive pregnancy test at Screening~* Women of childbearing potential not willing to use adequate contraception, defined as hormonal birth control or intrauterine device, during the trial and for 1 year after the last dose of daratumumab. For participants in the United States, the use of a double-barrier method is also considered adequate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: Daratumumab (Type: EXPERIMENTAL): None
- Dose Expansion: Daratumumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).